Skip to main content

Original Research

Business, Original Research
Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly
Sameer R. Ghate, PhD; Zhiyi Li, MBA, MA; Jackson Tang, MSc; Antonio Reis Nakasato, MD
Stakeholder Perspective
It’s About the Total Cost of Care
Gary M. Owens, MD
Read More
Clinical, Original Research
Analysis of Real-World Dosing Patterns for the 3 FDA-Approved Medications in the Treatment of Fibromyalgia
Craig White, PhD; Winghan Jacqueline Kwong, PharmD, PhD; Hilary Armstrong, PhD; Michael Behling; Jeffrey Niemira; Kathy Lang, PhD
Stakeholder Perspective
Real-World Drug Prescribing and Utilization Studies Can Inform Optimized Patient Care and Insurance Coverage
F. Randy Vogenberg, PhD, RPh
Read More
Original Research, Regulatory
Trends in Utilization, Spending, and Prices of Smoking-Cessation Medications in Medicaid Programs: 25 Years Empirical Data Analysis, 1991-2015
Xiaomeng Yue, BPharm, MS; Jeff Jianfei Guo, BPharm, MS, PhD; Patricia R. Wigle, PharmD
Stakeholder Perspective
The Importance and Benefits of Smoking-Cessation Therapy
Jack E. Fincham, PhD, RPh
Read More
Business, Original Research
Estimating the Real-World Cost of Diabetes Mellitus in the United States During an 8-Year Period Using 2 Cost Methodologies
Vincent J. Willey, PharmD; Sheldon Kong, PhD; Bingcao Wu, MS; Amit Raval, PhD; Todd Hobbs, MD; Andrea Windsheimer, PharmD; Gaurav Deshpande, MS, PhD; Ozgur Tunceli, PhD; Brian Sakurada, PharmD; Jonathan R. Bouchard, MS, RPh
Read More
Business, Original Research
The Prevalence and Payer Costs of Potentially Avoidable Emergent Care Visits for Suspected Amniotic Membrane Rupture in Pregnant Women
Christine Ferro, CHFP; Bruce S. Pyenson, FSA, MAAA; Jocelyn Lau, MPH; Mona Kelkar, MBA; Nancy Phillips, MD; Chi-Wei Lu, PhD; Percy Yeung, PhD; Gloria Bachmann, MD
Stakeholder Perspective
Interventions to Reduce Avoidable Pregnancy-Related Emergency Department Visits
Eliza Ng, MD
Read More
Business, Original Research
Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn’s Disease
Michele Wilson, MSPH; Aaron Lucas, PhD, MPH; Ann Cameron, MA, PhD; Michelle Luo, PhD
Read More
Clinical, Original Research
Assessing the Level of Patient-Specific Treatment Recommendations in Clinical Practice Guidelines for Hemodialysis Vascular Access in the United States
Gilbert L. Queeley, PhD; Ellen S. Campbell, PhD; Askal A. Ali, PhD
Stakeholder Perspective
The Challenge of Maintaining Vascular Access in Patients with End-Stage Renal Disease
Raymond L. Singer, MD, MMM, CPE
Read More
Business, Original Research
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy
Machaon M. K. Bonafede, PhD, MPH; Donna McMorrow, BS; Clare Proudfoot, PhD; Shraddha Shinde, MS, MBA; Andreas Kuznik, PhD; Chieh-I Chen, MPH
Read More
Clinical, Original Research
Prior Authorization for Elective Diagnostic Catheterization: The Value of Reviewers in Cases with Clinical Ambiguity
Adam C. Powell, PhD; Stephen E. Price, DPT, MBA; Khoa Nguyen, MS; Gary L. Smith, MS; James W. Long, BSBA; Uday U. Deshmukh, MD, MPH
Stakeholder Perspective
Standardized Documentation Can Improve Diagnostic Testing Decisions for Patients with Cardiovascular Disease
Raymond L. Singer, MD, MMM, CPE, FACS
Read More
Clinical, Original Research
Long-Term Outcomes of a Cardiovascular and Diabetes Risk-Reduction Program Initiated by a Self-Insured Employer
Nicole D. White, PharmD, CDE; Thomas L. Lenz, PharmD, FACLM; Maryann Z. Skrabal, PharmD, CDE; Jessica J. Skradski, PharmD; Louis Lipari, PharmD candidate
Stakeholder Perspective
Influencing Patient Outcomes Through Enhanced Multidisease-Focused Interventions
Jack E. Fincham, PhD, RPh
Read More
Page 7 of 11
Results 61 - 70 of 108